Last reviewed · How we verify
NCT05959928: Viture
Continuous Temperature Telemonitoring of Patients With COVID-19 and Other Infectious Diseases in Hospital at Home Using Viture
trial testing Continuous wearable thermometer placed on patient's armpit to monitor body temperature remotely in COVID-19 in 208 participants. Completed in 2 June 2021.
2 June 2021
Quick facts
| Lead sponsor | Vitio Medical S.L. |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 208 |
| Start date | 9 February 2021 |
| Primary completion | 2 June 2021 |
| Estimated completion | 2 June 2021 |
| Sites | 1 location across Spain |
Drugs / interventions tested
- Continuous wearable thermometer placed on patient's armpit to monitor body temperature remotely
Conditions studied
- COVID-19 — all drugs for COVID-19 →
- Infectious Disease — all drugs for Infectious Disease →
- Tract Infection, Urinary — all drugs for Tract Infection, Urinary →
- Bacteremia — all drugs for Bacteremia →
Sponsor
Vitio Medical S.L.
Who can join
18 and older, any sex, with COVID-19 or Infectious Disease. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The aim of this cohort study is to validate Viture®, a continuous temperature telemonitoring system, evaluating the level of agreement with a standard commercially available digital axillary thermometer. The study also aims to evaluate the safety and comfort of the system and to evaluate the impact that the introduction of Viture has on the health care practice of a HaH unit. Furthermore, the advantages of Viture compared to the standard method will be evaluated.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT05959928
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for COVID-19
Currently open trials in the same condition.
- NCT07183709 — Safety and Immunogenicity Trial of PepGNP-COVID19 Vaccine in Adults · Phase 1 · active not recruiting
- NCT07300839 — A Study to Learn About a COVID-19 Vaccine in Healthy Adults 50 Through 64 Years of Age · Phase 3 · active not recruiting
- NCT07221162 — A Safety and Immunogenicity Trial of Boost-2867 Vaccine, Via Intranasal and Intramuscular Routes · Phase 1 · recruiting
- NCT07215520 — Safety and Tolerability of a Newcastle Disease Virus-Based Mucosal COVID-19 Vaccine in Previously Vaccinated Adults · Phase 2 · recruiting
- NCT07222384 — A Study to Learn About BNT162b2 (LP.8.1)-Adapted Vaccine Against SARS-CoV-2 in Children 5 Through 11 Years of Age That A · Phase 3 · active not recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05959928 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Vitio Medical S.L.
- Last refreshed: 8 July 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05959928.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing